Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
This study is a Phase II study to determine the preliminary safety and efficacy of salvage radiation treatment after BCMA CAR-T therapy in subjects with RRMM.
The study population will consist of subjects with RRMM previously treated with SOC BCMA CAR-T cell therapy with active disease on the D30+ PET or other imaging scan after CAR-T infusion. Patients who are planned for salvage chemotherapy less than 14 days after completion of radiation treatment will be excluded.
Radiation treatment will be to bony or soft tissue plasmacytomas in up to five radiation treatment fields to 10-20Gy (or equivalent dose in 2Gy fractions of 10-21Gy). Final dose, target, and technique are per treating radiation physician discretion within these guidelines.
Thirty patients will be enrolled. The co-primary endpoints are objective response rate (ORR) at 6 months and duration of response (DOR) among responders.
|Condition or Disease||Intervention/Treatment||Phase|
• The primary objective of the study is to evaluate the preliminary efficacy of salvage radiation therapy after BCMA CAR-T cell therapy in subjects with RRMM.
• Evaluate the safety of and other efficacy parameters of radiation treatment after BCMA CAR-T cell therapy in subjects with RRMM
Evaluate the immunophenotype and/or expression profile, and perform functional bulk and single cell analysis of CAR T cells, endogenous T cells as well as other immune cells in the blood, bone marrow and/or tumor tissue with BCMA CAR-T therapy and RT
Evaluate changes in the levels of cytokines, chemokines, and soluble factors in the blood with BCMA CAR-T therapy and RT
Evaluate changes in T cell receptor repertoire with BCMA CAR-T therapy and RT
Evaluate gut microbiome of patients treated with BCMA CAR-T therapy and RT
Arms and Interventions
|Experimental: Radiation Therapy
Radiation treatment will be to bony or soft tissue plasmacytomas in up to five radiation treatment fields to 10-20Gy (or equivalent dose in 2Gy fractions of 10-21Gy
Drug: Radiation Therapy
Given by Infusion
Primary Outcome Measures
- Overall response rate (ORR) [through study completion, an average of 1 year]
Percentage of subjects who achieved partial response (PR) or better according to IMWG Uniform Response Criteria for Multiple Myeloma (Kumar, 2016)
- Duration of response (DoR) among responders [through study completion, an average of 1 year]
Time from first documentation of response (PR or greater) to first documentation of progressive disease (PD) or death from any cause, whichever occurs first
Subjects must satisfy the following criteria to be enrolled in the study:
Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF)
Subject is diagnosed with multiple myeloma
Subject previously received treatment with standard of care BCMA CAR-T cell therapy
Day 30 or later PET scan or other imaging scan after CAR-T infusion shows active disease
Subject has at least one myeloma lesion (plasmacytoma either in bone or soft tissue) that can be treated with radiation
Able to provide informed consent
The presence of any of the following will exclude a subject from enrollment:
Subjects in whom salvage chemotherapy is planned less than 14 days after the completion of radiation treatment
Subject is undergoing active treatment for another malignancy other than multiple myeloma
Pregnant women will be excluded from this study.
Contacts and Locations
|1||M D Anderson Cancer Center||Houston||Texas||United States||77030|
Sponsors and Collaborators
- M.D. Anderson Cancer Center
- Principal Investigator: Penny Fang, MD, M.D. Anderson Cancer Center
Study Documents (Full-Text)None provided.